The crown passes: mRNA's new king and old king

On September 13, 2024, riding the tailwind of PD-L1/VEGF therapeutics, BioNTech’s stock surged 17.52%, reaching $123.40 per share and a market capitalization of $29.3 billion. This marked a true turning point—officially surpassing its longtime rival Moderna, whose market cap stood at $26.2 billion. Just months earlier, Moderna’s market value had been nearly triple that of BioNTech. As of February 14, BioNTech’s market cap stood at $28.7 billion, while Moderna’s had plummeted to $12.7 billion—a gap that continues to widen. This reversal is highly dramatic. During the pandemic, Moderna dominated BioNTech as the undisputed 'first mRNA IPO': at its 2021 peak, its market cap soared to $195.5 billion. Elon Musk even publicly declared mRNA technology all-powerful, predicting Moderna’s market cap would exceed $1 trillion. Though BioNTech also reaped substantial pandemic dividends, it remained far behind. Yet once pandemic-driven demand faded, the two companies diverged sharply in fate: Moderna sank into difficulty due to overreliance on mRNA vaccines, whereas BioNTech stabilized its stock decline through strategic oncology investments and its China pipeline. Since the start of 2024, BioNTech’s stock has risen 13%, while Moderna’s has plunged 67%. Though BioNTech’s actual gain is modest, against the backdrop of its rival’s collapse, the uptick proved sufficient—and enabled its ascension to the top spot. Wall Street’s divergent views on mRNA giants reflect, fundamentally, a contest between strategic discipline and timing of opportunity. Of course, this is far from the final chapter. The allure of biotech lies precisely in its uncertainty: when Moderna combines its mRNA tumor vaccine with CRISPR technology, or when BioNTech’s bispecific antibody pipeline hits clinical setbacks, the balance of power may tilt once again. / 01 / The perennial runner-up rises BioNTech and Moderna are, in many ways, fated rivals. These two mRNA pioneers were founded almost simultaneously; after more than a decade of R&D, they successively launched COVID-19 vaccines during the pandemic—and ranked 18th and 19th globally among pharmaceutical companies in 2021 by revenue ($18.977 billion and $18.471 billion, respectively). In proving mRNA’s boundless potential, they also demonstrated that opportunity truly favors those who prepare—and persist. Yet their treatment on Wall Street differed markedly. Since the pandemic, BioNTech has remained the 'perennial runner-up.' Initially, at their respective Nasdaq listings, their starting valuations were not vastly different—$3.2 billion for BioNTech versus $4.7 billion for Moderna. After their COVID-19 vaccines launched, Moderna surged ahead relentlessly, peaking at a $195.5 billion market cap—even overtaking century-old Merck. BioNTech, meanwhile, was overshadowed by its partner Pfizer, and its market cap lingered around $100 billion. The turning point came in 2024. In the post-pandemic era, Moderna doubled down exclusively on mRNA vaccines. Its short-to-medium-term overdependence on revenues from COVID-19 and RSV vaccines repeatedly led to earnings missing market expectations—and its stock hit successive new lows.

MRD technology makes its first overseas debut; IVD firms build Chinese brands!

Leveraging a technology named 'Zhēn Xīn Ān–MRD' (HeartPeace–MRD), this major Chinese enterprise specializing in tumor genetic testing and non-traditional IVD has attracted the attention of a Nasdaq-listed company—marking the first overseas debut of MRD technology and launching a global commercialization plan beginning in Southeast Asia. It bears noting that such technology export is extremely rare within the IVD sector—and uncommon across the broader healthcare industry—signaling the rise of Chinese medical technology. The protagonist here is Tongshu Genetics, which recently entered into a globally strategic licensing agreement with Nasdaq-listed BioNexus Gene Lab Corp. (BGLC). Under the agreement, Tongshu Genetics has licensed its independently developed core technology—the 'Zhēn Xīn Ān–MRD' platform for monitoring tumor minimal residual disease (MRD)—to BGLC and its partners. This move makes Tongshu Genetics the first domestic company to successfully export MRD technology overseas, providing strong validation of the international competitiveness of homegrown Chinese innovation. Historically, China’s medical device industry has focused primarily on exporting equipment or supplying raw materials; high-value, innovative technology licensing abroad remains exceedingly rare. Tongshu Genetics’ successful international rollout of its core MRD monitoring platform thus represents a breakthrough 'from zero to one.' Within a certain scope, this demonstrates that China’s frontier innovations in precision oncology diagnostics have advanced beyond 'catching up' and 'running alongside' global leaders—entering a new phase of 'leading' and 'exporting.' Now it’s our turn to say: business knows no borders. Per the agreement, both parties will adopt a phased, systematic global rollout strategy. Phase One will focus initially on the Association of Southeast Asian Nations (ASEAN) region—including key countries such as Singapore, Malaysia, and Thailand—to achieve market authorization, localized promotion, and commercial application of the VitaGuard™ platform (built upon the 'Zhēn Xīn Ān–MRD' technology). Success in this phase will provide critical operational data, clinical practice feedback, and business model validation for subsequent steps. The ultimate goal of the collaboration is to jointly advance regulatory approval of this MRD technology by the U.S. FDA and the European Medicines Agency (EMA), culminating in full-scale commercialization across mainstream markets in Europe and the United States. This 'ASEAN-first, Europe-and-U.S.-focused' strategic roadmap reflects both parties’ firm confidence in the global applicability and value of the 'Zhēn Xīn Ān–MRD' technology. Undoubtedly, this is recognition of technical excellence—backed by robust, scientifically validated clinical data. The technology employs the internationally leading second-generation 'tumor-naïve' detection approach. Unlike conventional methods requiring matched tumor tissue samples for comparison, the tumor-naïve method achieves ultra-sensitive detection of circulating tumor DNA (ctDNA) using blood samples alone—greatly enhancing test accessibility and convenience. Underpinning this technical superiority is a rigorous, science-based clinical validation framework. Based on large-scale, multicenter clinical trial data, the 'Zhēn Xīn Ān–MRD' technology demonstrates outstanding clinical performance, with a negative predictive value (NPV) as high as 94.4%. This means that when the test yields a negative result, patients have an exceptionally high probability of truly lacking minimal residual disease—providing clinicians with a critical, reliable basis for guiding subsequent treatment decisions. Moreover, related studies have already gained broad recognition from the international academic community, with findings published in multiple high-impact international journals—accumulating a total impact factor exceeding 170.

BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)

Apr 14, 2026

BioNexus Gene Lab reported fiscal-year revenue of $7.42 million, down 21.9% due to lower Chemrex volume and foreign exchange. Despite an operating loss increase, gross margins improved to 14.7% as the company expanded into diagnostics.

TradingView — Track All Markets

2026-02-23

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

2026-03-12

BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to Lead VitaGuard™ MRD Commercialization

2026-04-04

BioNexus Gene Lab Corp Stock Drops 3% on Poor Ratings

2026-04-14

BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)

2026-05-15

BioNexus Gene Lab Corp Q1 2026 Earnings: Revenue $22.84K, EPS ($0.23)